dromlakhani Adjust anti-hypertensive medications to improve PA screening accuracy
STEP 1 — Gather Information
Document the patient’s current antihypertensive medications (especially ACE inhibitors, ARBs, beta-blockers, diuretics), hypertension control status, serum potassium, and the indication for PA screening (e.g., resistant hypertension, hypokalemia, incidental adrenal mass).
STEP 2 — Rule In / Rule Out
If the patient is on ACE inhibitors, ARBs, beta-blockers, or diuretics that may suppress renin or alter aldosterone, proceed to medication adjustment; otherwise, continue the current regimen and obtain screening ARR/PAC.
STEP 3 — Classify or Stratify
Choose a replacement antihypertensive class known to minimally affect the ARR: calcium channel blocker (e.g., amlodipine), alpha-blocker (e.g., doxazosin), or a combination thereof, considering comorbidities and contraindications.
STEP 4 — Decide
Switch the interfering antihypertensive to the selected calcium channel blocker, alpha-blocker, or combination, ensure hypertension and hypokalemia remain appropriately treated, then obtain screening ARR (≥200) and PAC (≥60 pg/mL) by CLEIA.
Clinical Guardrails / Mimics / Pitfalls
Do not discontinue effective antihypertensive therapy solely to facilitate screening; avoid substituting with agents that worsen hypokalemia (e.g., thiazide diuretics) without potassium supplementation; do not delay screening indefinitely while adjusting medications; remember that medication changes may take days to weeks to fully influence ARR.
Concrete Clinical Example
A 58‑year‑old woman on lisinopril 20 mg daily presents with resistant hypertension and spontaneous hypokalemia; initial ARR is 150 (borderline). After switching lisinopril to amlodipine 5 mg daily, repeat ARR rises to 230 with PAC 78 pg/mL, leading to a positive screen and subsequent confirmatory testing.
Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2021